{
  "variant_id": {
    "Gene": "EGFR",
    "Protein_Change": {
      "ref": "L",
      "alt": "R",
      "position": "858"
    },
    "variant_string_id": "EGFR L858R"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "The paper states that 'EGFR L858R leads to constitutive activation of the kinase domain, driving uncontrolled cell proliferation in non-small cell lung cancer.'",
      "judgment": "Yes",
      "reasoning": "The disease mechanism is clearly defined as constitutive kinase activation leading to uncontrolled cell growth."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "The study used kinase activity assays to measure EGFR phosphorylation levels in transfected cells.",
      "judgment": "Yes",
      "reasoning": "Kinase activity assays directly assess the mechanism of constitutive activation described for this disease.",
      "next_step_or_outcome": "Proceed to Step 3"
    },
    {
      "step_name": "Step 3a: Basic Controls and Replicates",
      "extracted_paper_info": "The methods state that 'all experiments included wild-type EGFR as a negative control and the known activating mutant EGFR T790M as a positive control, with n=5 replicates.'",
      "judgment": "Yes",
      "reasoning": "Both negative and positive controls were used with multiple replicates.",
      "next_step_or_outcome": "Proceed to Step 3c"
    },
    {
      "step_name": "Step 3c: Variant Controls",
      "extracted_paper_info": "The study tested 12 known pathogenic variants and 8 known benign variants across the kinase domain.",
      "judgment": "Yes",
      "reasoning": "A sufficient number of known pathogenic and benign variants were used as controls.",
      "next_step_or_outcome": "Proceed to Step 4"
    },
    {
      "step_name": "Step 4a: Statistical Analyses",
      "extracted_paper_info": "The paper reports 'p=0.0002 for kinase activity compared to wild-type, with an OddsPath of 23.5 for pathogenicity.'",
      "judgment": "Yes",
      "reasoning": "OddsPath is calculated and statistically significant.",
      "next_step_or_outcome": "Proceed to Step 4c"
    },
    {
      "step_name": "Step 4c: Correlate OddsPath",
      "extracted_paper_info": "OddsPath of 23.5 for EGFR L858R was calculated from kinase activity and clinical correlation.",
      "judgment": "Yes",
      "reasoning": "OddsPath exceeds 18.7 threshold for very strong pathogenic evidence.",
      "next_step_or_outcome": "Final assessment"
    }
  ],
  "final_evidence_strength": {
    "type": "Pathogenic",
    "strength": "PS3_very_strong"
  },
  "overall_conclusion": "EGFR L858R shows very strong pathogenic evidence due to constitutive kinase activation with OddsPath of 23.5, using appropriate controls and multiple replicates."
}